- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06710743
Determination of the Glycemic Index Values of 10 Cereal-based Products
November 26, 2024 updated by: PepsiCo Global R&D
To determine the Glycemic index values for 10 cereal-based products
Study Overview
Status
Completed
Conditions
Detailed Description
To determine the Glycemic index values for 10 cereal-based products per international standard (ISO26642:2010) for glycemic index determination.
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2006
- Sydney University's Glycemic Index Research Service (SUGiRS)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 10 healthy participants, male and female (non-pregnant, non-lactating) of mixed ethnicity, aged between 18 - 65 y
- BMI: 18 - 25.0 kg/m2 (bounds included)
- Non smokers
- Normal glucose tolerance (assessed by 50 gram oral glucose tolerance test performed within the last 30 days: fasting <6 mM, 2 hr glucose <7.8 mM)
- Stable weight and dietary habits. Normal eating patterns and no history of eating disorders or recent dieting
- Normal sleep patterns (ie. at least 6 hours of sleep per night)
- The participants are required to avoid alcohol and unusual levels of food intake and physical activity for the 24 hours before each test session.
- Absence of health conditions that would prevent fulfillment of study requirements as judged by the Investigator on the basis of medical history. Understanding the study procedures and willing to provide informed consent to participate in the study and authorization to release relevant protected health information to the study investigator.
Exclusion Criteria:
- Food allergy or intolerance to the study ingredients (eg. gluten, etc.)
- Regularly taking prescription medication other than standard contraceptive medication
- Taking any medications known to affect glucose tolerance (eg. acetylsalicylic acid, thyroxin, vitamins and mineral supplements or drugs to treat hypertension or osteoporosis)
- Suffering from any illness or disease
- Following a restricted diet
- Smokers
- Eating disorders
- Abnormal glucose tolerance or known history of diabetes mellitus.
- Individuals currently participating in other acute metabolic studies
- Failure to meet any one of the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Reference food
Glucodin powder solution
|
Glucodin powder diluted with water
|
|
Experimental: Food 1
Quaker Whole Oats
|
Variety of cooked or flake cereal
|
|
Experimental: Food 2
Quaker Quick Cooking White Oats
|
Variety of cooked or flake cereal
|
|
Experimental: Food 3
Saffola Oats
|
Variety of cooked or flake cereal
|
|
Experimental: Food 4
Quaker Oats
|
Variety of cooked or flake cereal
|
|
Experimental: Food 5
Quaker Oats Multigrain
|
Variety of cooked or flake cereal
|
|
Experimental: Food 6
Ragi Flakes
|
Variety of cooked or flake cereal
|
|
Experimental: Food 7
Bajra Flakes
|
Variety of cooked or flake cereal
|
|
Experimental: Food 8
Jowar Flakes
|
Variety of cooked or flake cereal
|
|
Experimental: Food 9
Maltabella
|
Variety of cooked or flake cereal
|
|
Experimental: Food 10
FutureLife Smart + White Oats
|
Variety of cooked or flake cereal
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic index (GI) values
Time Frame: Two hour test session per visit. Visits must be at least two days apart. Including Screening, the study duration is approximately four to eleven weeks depending on whether participants are available to be tested one, two or three times per week.
|
Comparison of Glycemic index (GI) values of 10 different cereal-based products and the reference food (glucose solution assigned GI=100 by definition)
|
Two hour test session per visit. Visits must be at least two days apart. Including Screening, the study duration is approximately four to eleven weeks depending on whether participants are available to be tested one, two or three times per week.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Richa Bharti, MS, PepsiCo R&D Life Sciences
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2024
Primary Completion (Actual)
September 27, 2024
Study Completion (Actual)
September 27, 2024
Study Registration Dates
First Submitted
November 25, 2024
First Submitted That Met QC Criteria
November 26, 2024
First Posted (Actual)
November 29, 2024
Study Record Updates
Last Update Posted (Actual)
November 29, 2024
Last Update Submitted That Met QC Criteria
November 26, 2024
Last Verified
November 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PEP-2402
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of North Carolina, Chapel HillAmerican Diabetes AssociationNot yet recruitingType 2 Diabetes Mellitus (T2DM) | Diabetes (DM) | Insulin Dependent Diabetes | Type 1 Diabetes (T1D) | Diabetes Education | Diabetes Care | Diabetes (Insulin-requiring, Type 1 or Type 2)United States
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
COUR Pharmaceutical Development Company, Inc.RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)United States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceCompletedType 2 Diabetes Mellitus | Pre DiabetesAustralia
Clinical Trials on Glucose solution Day 1, Day 8, and Day 15
-
Boehringer IngelheimCompleted
-
Queen's University, BelfastCompletedHealthyUnited Kingdom
-
St Stephens Aids TrustCompleted
-
Windy Hill Medical, Inc.UnknownDuctal Carcinoma In SituUnited States
-
Youssef DaaliCompleted
-
Alexandra Hospital, Athens, GreeceHellenic Society of GastroenterologyCompletedH.Pylori Infection | H.Pylori Gastrointestinal Disease | H. Pylori Associated Phlegmonous GastritisGreece
-
CooperVision, Inc.Recruiting
-
Boston University Charles River CampusNot yet recruitingAging | Memory | Noninvasive Brain Stimulation
-
Hillerod Hospital, DenmarkUnknownPhysical Activity | Acute Ischemic Stroke | AccelerometerDenmark
-
Pharmbio Korea Co., Ltd.Not yet recruitingColonic Diseases | Digestive System Disease | Gastrointestinal Disease | Intestinal DiseaseKorea, Republic of